Authors: Felasfa M Wodajo
Publish Date: 2016/04/13
Volume: 475, Issue: 3, Pages: 705-707
Abstract
The author certifies that he or a member of his immediate family has no funding or commercial associations eg consultancies stock ownership equity interest patent/licensing arrangements etc that might pose a conflict of interest in connection with the submitted articleThe current generation of skeletal osseointegration implants for oncologic indications can be traced back to the clearance of the Compress® Biomet Warsaw IN USA implant by the FDA in December 2003 7 Since then numerous papers have attested to its durability and reliability for diaphyseal bone fixation 2 6 8 10In the current study Kagan and colleagues extended our knowledge of this implant design by searching for patterns of implant failure In their largest retrospective series to date the authors reviewed 116 implants and found that the anatomic location of the implant predicted survival of their reconstructions Additionally neither the age of the patient nor chemotherapy were associated with differences in implant survival The most common reason for failure was infection These findings are in line with other recent oncologic series of cemented diaphyseal fixation 4
Keywords: